InvestorsHub Logo
Followers 40
Posts 7682
Boards Moderated 1
Alias Born 01/04/2006

Re: califax post# 7804

Thursday, 12/23/2010 11:23:22 PM

Thursday, December 23, 2010 11:23:22 PM

Post# of 8473
Repros shares skyrocket on drug news
Houston Business Journal - by Greg Barr
Date: Thursday, December 23, 2010, 2:28pm CST - Last Modified: Thursday, December 23, 2010, 4:57pm CST
Related:
Health Care
Related News

Repros shares up on successful Proellex test
Repros shares fall on FDA recommendation
IDEV Technologies gets FDA approval for stent systems
Doing biotech business in Japan 101
Repros regains stock listing compliance

Shares of Repros Therapeutics Inc. nearly doubled in value Thursday in heavy volume after the company reported positive developments for its experimental testosterone deficiency drug, Androxal.

Repros (NASDAQ: RPRX) said in a statement that it had sent additional data to the U.S. Food and Drug Administration showing that a single assessment of testosterone levels collected in the morning correlates to maximum and average levels of testosterone during a 24-hour period in subjects taking Androxal.


Read more: Repros shares skyrocket on drug news | Houston Business Journal
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RPRX News